CAS 162394-19-6|Palifermin
Introduction：Basic information about CAS 162394-19-6|Palifermin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Palifermin | ||
|---|---|---|---|
| CAS Number | 162394-19-6 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | / | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Palifermin |
|---|
Palifermin BiologicalActivity
| Description | Palifermin is the recombinant human keratinocyte growth factor (KGF). Palifermin induces cells growth. Palifermin shows antimucotoxic. Palifermin can be used to decrease the oral mucosal injury induced by cytotoxic therapy[1][2][3]. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology |
| In Vitro | Palifermin (0-100 ng/mL; 48 h) stimulates the growth of TE-8, TE-11 cells[1]. Cell Proliferation Assay[1] Cell Line: TE-1, TE-8, TE-11 cells Concentration: 0, 1, 10 100 ng/mL Incubation Time: 48 h Result: Increased the proliferation for TE-8, TE-11 cells and did not stimulate the growth of TE-1 cells. |
| In Vivo | Palifermin (10 mg/kg for single dose or 3 mg/kg for 3 times; daily for 3 days) reduces diarrhea and increases survival following Irinotecan treatment in tumor-bearing DA rats[2]. Palifermin (5 mg/kg; s.c.) shows effectiveness on oral mucositis induced by fractionated irradiation[3]. Animal Model: DA rats[2] Dosage: 10 mg/kg for single dose or 3 mg/kg for 3 times Administration: Daily for 3 days prior to chemotherapy treatment Result: Reduced diarrhea and increased survival following Irinotecan treatment. Animal Model: Mouse with 5*3 Gy/week irradiation (tongue model)[3] Dosage: 5 mg/kg Administration: S.c; at -3, +4, +11 days or +4, +11, +18 days or -3, +4, +11, +18 days Result: Showed effectiveness on oral mucositis (mouse) induced by fractionated irradiation. |
| References | [1]. Spielberger R, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004 Dec 16;351(25):2590-8. [2]. Yoshino M, et al. Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. Int J Oncol. 2007 Oct;31(4):721-8. [3]. Dörr W, et al. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol. 2005 Apr;75(1):99-105. |
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
